Quicker Psychedelic Drugs Offer Investors a Better Trip

Psychedelic drug companies could regain investor confidence if therapies become shorter-duration, improving commercial viability. The column argues that after the 2021-2022 bubble in psychedelic stocks burst, capital and confidence are starting to return, supported by encouraging clinical trial signals and political openness from senior Trump administration officials to using these drugs to address mental health conditions like depression. A key barrier to commercialization is session length: patients taking psilocybin (found in magic mushrooms) or LSD may need supervised experiences lasting roughly six to 12 hours. The argument is that quicker-acting psychedelic options could reduce the burden on providers and make scaling treatment more practical, which in turn could support stronger market performance for the sector.